TAKEDA NEARS FIRST THERAPY FOR ROOT CAUSE OF NARCOLEPSY

Summary from the TLDR newsletter

Takeda Pharmaceutical has developed a drug that significantly improves outcomes for narcoleptic patients. The drug, called oveporexton, could become the first treatment to target the root cause of the chronic sleep disorder. Patients who take the drug experience increased daytime alertness, fewer episodes of sudden muscle tone loss, and overall improvement in quality of life. No serious side effects have been reported, but some patients report insomnia and increased urinary urgency and frequency. The company plans to file for regulatory approvals globally by March.